Clinical trials: Uncomplicated Urinary Tract Infection
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections
This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response…
- Trial name
- NCT05138822
- Testing
- GSK3882347, Nitrofurantoin
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlaxoSmithKline
Uncomplicated Urinary Tract Infections
Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem-etzadroxil/probenecid versus oral ciprofloxacin for treatment of uncomplicated urinary tract…
- Trial name
- NCT03354598
- Testing
- Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin
- Where
- 60 sites in United States
- Volunteers
- 1,671 people
- Sponsor
- Iterum Therapeutics, International Limited
Uncomplicated Urinary Tract Infection, Cystitis
Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis
The purpose of this study is to evaluate the safety and efficacy of oral omadacycline as compared to oral nitrofurantoin in the treatment of female adults with cystitis.
- Trial name
- NCT03425396
- Testing
- Omadacycline tablets, Nitrofurantoin capsules
- Where
- 23 sites in United States
- Volunteers
- 225 people
- Sponsor
- Paratek Pharmaceuticals Inc
Urinary Tract Infection (UTI), Complicated Urinary Tract Infection
Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) for the treatment of complicated urinary tract infection (cUTI) including…
- Conditions
- Urinary Tract Infection (UTI), Complicated Urinary Tract Infection, Pyelonephritis, Uncomplicated Pyelonephritis
- Trial name
- NCT02728089
- Testing
- MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC